#ASCO23 Healthcare Social Media Analytics
Top Influencers of the #ASCO23 healthcare social media hashtag.
Related Articles
MedNews Week
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Chandler Park, M.D., F.A.C.P. on LinkedIn: #harryyoon #thachgiaotruong #maxwellkrem #jessicageiger #inspireβ¦
βοΈWhat a FUN precision medicine and immunotherapy meeting at Cleveland Clinic Thank you to my good friend Shilpa Gupta, MD for co-moderating this incredibleβ¦
Yan Leyfman: ASCO Breakthrough was an unparalleled experience – OncoDaily
Yan Leyfman: ASCO Breakthrough was an unparalleled experience / ASCO, cacner advances, cancer, Cancer research, clinical trials, Julie Gralow, Lynn Schuchter,
2023β―Year in review: Early breast cancer
The results of several studies aiming to tailor early breast cancer treatment to individual risk were released in 2023. Axillary lymph node dissections and radiotherapy…
MedNews Week
Connecting audiences with high quality, current medical information in the fight against misinformation. Follow Us to Stay Connected & Updated! Clubhouse: https://www.clubhouse.com/house/mednews-week Linktr.ee: https://linktr.ee/themednewsweek?subscribe LinkedIn:…
100 Influential Women in Oncology: Key Opinion Leaders to follow on Social Media in 2023: Part 8 – Oncodaily | Oncology News, Insights, Stories
Once again, it’s Saturday, and we continue OncoDailyβs series, ‘100 Influential Women in Oncology: Key Opinion Leaders to Follow on Social Media in 2023.’ As
Oligometastatic Bladder Cancer: Defining a Novel Entity
Over the past decade, there has been substantial progress in the therapeutic management of patients with metastatic bladder cancer (BCa), notably with the recent emergence…
Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial
Nature Medicine – In a phase 2 trial, the combination of gemcitabine, cisplatin and anti-PD-1 led to a clinical complete response in 43% of patients…
Atezolizumab Plus Magrolimab, Niraparib, or Tocilizumab in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Randomized Umbrella Study
Abstract. Purpose: The MORPHEUS platform was designed to identify early efficacy signals and evaluate the safety of novel immunotherapy combinations across cancer types. The phase…
The OncoAlert Newsletter is NOW OUT Click to Register
The OncoAlert Newsletter is now out for June 23-29, 2023